King Saud University Repository >
King Saud University >
Health Colleges >
College of Pharmacy >
College of Pharmacy >

Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/17094

Title: Glucogon-like peptide-1 derives and dipeptidyl peptidase-IV inhibitors
Authors: Mohamed A. Al-Omar
PhD, Mohammed N
Al-Arifi, PhD.
Issue Date: 2005
Publisher: Saudi Med J
Abstract: Glucagon-like peptide (GLP-1) is an endogenous insulinotropic/glucagonostatic hormone that acts in a self-limiting mechanism. It is a multifunctional hormone that leads to insulin release stimulation, liver glucagon breakdown suppression, upregulation of islet cell proliferation, and neogenesis and retardation of gastric emptying. The short half-life and high renal clearance due to degradation via dipeptidyl peptidase-IV (DPP-IV), and active glomerular filtration rate make this hormone ineffectual as an exogenous agent. More stable and long acting GLP-1 analogues and DPP-1 inhibitors have been developed with promising clinical value for the treatment of type-2 diabetes. The GLP-1 derivatives have the advantage of decreasing body weight while the DPP-IV inhibitors can be administered orally up to once daily. The mechanism of action as well as the tolerable side effect is astounding. This review article covers this new generation of anti-diabetics.
URI: http://hdl.handle.net/123456789/17094
Appears in Collections:College of Pharmacy

Files in This Item:

File Description SizeFormat
11.doc52.5 kBMicrosoft WordView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


DSpace Software Copyright © 2002-2009 MIT and Hewlett-Packard - Feedback